teclistamab,talquetamab,daratumumab
genmab,janssen
['redirectt-1', 'mmsm', 'multiple myeloma']
#eha2023 presents redirectt-1 ph1 trial combining two subq bispecific abs in pts w/ r/r multiple myeloma. crs was common (over 75%) but discontinuation due to aes was low (6%). 6 drug-related deaths were reported #mmsm orr 71.4% (all dose levels) and pfs 6 mo (1/2) 
The Lancet Haematology is a world-leading #haematology journal publishing peer-reviewed research and reviews, opinion, and news. #hematology